chartexchange

SAB Biotherapeutics Inc (SABS) (Q3 2026) Earnings Call Highlights: FDA Fast-Track Win, Full ...

GuruFocus | Nov 5, 2026 6:15 PM EST

SAB Biotherapeutics Inc (SABS) advances SAB-142 with FDA Fast-Track designation, completes adult and adolescent enrollment in the Phase IIb Safeguard study, and extends its cash runway through 2028. Related Stocks: SABS ,

Read original article